Review
doi: 10.1016/j.jfms.2004.08.005.Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate
Affiliations
- PMID:15686976
- PMCID: PMC10911555
- DOI: 10.1016/j.jfms.2004.08.005
Item in Clipboard
Review
Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate
Ruiyu Pu et al. J Feline Med Surg.2005 Feb.
Display options
Format
Display options
Format
Abstract
Vaccine trials were undertaken to determine whether the Fel-O-Vax FIV, a commercial dual-subtype (subtypes A and D) feline immunodeficiency virus (FIV) vaccine, is effective against a subtype B FIV isolate. Current results demonstrate the Fel-O-Vax FIV to be effective against a subtype B virus, a subtype reported to be the most common in the USA.
Figures
The phylogenetic tree distribution (panel A), amino acid comparison (panel B), and recombination analysis (panel C) of the vaccine viruses and challenge virus used in current studies 1 and 2, and the virus (FIVBang) reported for prototype dual-subtype FIV vaccine studies (Pu et al 2001). The two vaccine viruses (boxes) and two challenge viruses (ovals), along with known FIV strains, are displayed in a phylogenetic tree of the FIV envelope (env). An unrooted phylogenetic tree was created using the BLOSUM matrix and neighbor-joining algorithm based on the Kimura two-parameter correction (Saitou and Nei 1987, Kimura 1980). Support at each internal node was assessed using 1000 bootstrap samplings and each tree was visualized using Tree View (Felsenstein 1989, Page 1996). All full-length isolates from NCBI data bank (Accession numbers M36968, X60725, M73964, L06312, X57002, M25381, L00607, D37813, X69496, X57001, X69494, D37811, D37815, AF474246, AF452126, D37812, D37816, D37814, E03581, AY621093, D37817, AY621094, U11820, AY620002) have been used with the exception of those based on partial sequences, which are designated in italics (CaBCpady02C, LP-24, LP-20, M2) (Accession numbers U02392, AB027304, AB027302, X69501). Isolates from Japan are designated with Jn, and isolates from USA are designated with the state abbreviation followed by the name of the virus. The amino acid (aa) sequence comparisons (panel B) between the vaccine and challenge strains used in our studies further demonstrate that both vaccine strains (FIVPet and FIVShi) had the greatest % aa difference from subtype B FIVFC1 at all viral proteins (Gag, Pol, Env) analyzed. The recombination analysis (panel C) of structural and polymerase genes of the vaccine and challenge strains was based on phylogenetic tree distributions of the FIV group-specific antigen (gag, tree not shown), FIV polymerase (pol, tree not shown), and FIVenv (panel A). FIVBang is a recombinant of subtypes A and B, and FIVFC1 belongs to subtype B atgag,pol andenv.
Similar articles
- Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats.Kusuhara H, Hohdatsu T, Okumura M, Sato K, Suzuki Y, Motokawa K, Gemma T, Watanabe R, Huang C, Arai S, Koyama H.Kusuhara H, et al.Vet Microbiol. 2005 Jul 1;108(3-4):155-65. doi: 10.1016/j.vetmic.2005.02.014.Vet Microbiol. 2005.PMID:15899558
- Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.Tellier MC, Pu R, Pollock D, Vitsky A, Tartaglia J, Paoletti E, Yamamoto JK.Tellier MC, et al.AIDS. 1998 Jan 1;12(1):11-8. doi: 10.1097/00002030-199801000-00002.AIDS. 1998.PMID:9456250
- Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies.Coleman JK, Pu R, Martin MM, Noon-Song EN, Zwijnenberg R, Yamamoto JK.Coleman JK, et al.Vaccine. 2014 Feb 3;32(6):746-54. doi: 10.1016/j.vaccine.2013.05.024. Epub 2013 Jun 22.Vaccine. 2014.PMID:23800540Free PMC article.
- Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.Sahay B, Yamamoto JK.Sahay B, et al.Viruses. 2018 May 22;10(5):277. doi: 10.3390/v10050277.Viruses. 2018.PMID:29789450Free PMC article.Review.
- Feline immunodeficiency virus model for designing HIV/AIDS vaccines.Yamamoto JK, Sanou MP, Abbott JR, Coleman JK.Yamamoto JK, et al.Curr HIV Res. 2010 Jan;8(1):14-25. doi: 10.2174/157016210790416361.Curr HIV Res. 2010.PMID:20210778Free PMC article.Review.
Cited by
- A door-to-door prevalence study of feline immunodeficiency virus in an Australian suburb.Chang-Fung-Martel J, Gummow B, Burgess G, Fenton E, Squires R.Chang-Fung-Martel J, et al.J Feline Med Surg. 2013 Dec;15(12):1070-8. doi: 10.1177/1098612X13491959. Epub 2013 Jun 5.J Feline Med Surg. 2013.PMID:23739036Free PMC article.
- 2008 American Association of Feline Practitioners' feline retrovirus management guidelines.Levy J, Crawford C, Hartmann K, Hofmann-Lehmann R, Little S, Sundahl E, Thayer V.Levy J, et al.J Feline Med Surg. 2008 Jul;10(3):300-16. doi: 10.1016/j.jfms.2008.03.002. Epub 2008 May 2.J Feline Med Surg. 2008.PMID:18455463Free PMC article.
- Feline leukemia and feline immunodeficiency virus in Canada - A comment.Doornenbal E, Ingwersen W, Cloutier G.Doornenbal E, et al.Can Vet J. 2012 Jan;53(1):9-10; author reply 10.Can Vet J. 2012.PMID:22753957Free PMC article.No abstract available.
- Advances in FIV vaccine technology.Uhl EW, Martin M, Coleman JK, Yamamoto JK.Uhl EW, et al.Vet Immunol Immunopathol. 2008 May 15;123(1-2):65-80. doi: 10.1016/j.vetimm.2008.01.030. Epub 2008 Jan 20.Vet Immunol Immunopathol. 2008.PMID:18295907Free PMC article.Review.
- Selective expansion of viral variants following experimental transmission of a reconstituted feline immunodeficiency virus quasispecies.Willett BJ, Kraase M, Logan N, McMonagle E, Varela M, Hosie MJ.Willett BJ, et al.PLoS One. 2013;8(1):e54871. doi: 10.1371/journal.pone.0054871. Epub 2013 Jan 23.PLoS One. 2013.PMID:23372784Free PMC article.
References
- Bachmann M.H., Mathiason-Dubard C., Learn G.H., Rodrigo A.G., Sodora D.L., Mazzetti P., Hoover E.A., Mullins J.I. Genetic diversity of feline immunodeficiency virus: dual infection, recombination, and indistinct evolutionary rates among envelope sequence clades, Journal of Virology 71, 1997, 4241–4253. - PMC - PubMed
- Berlinski PJ, Gibson JK, Forester NJ, Martin S. (2003) Further investigation into the increased susceptibility of cats to feline immunodeficiency virus (FIV) after vaccination with parenteral vaccines. In: 21st Annual American College of Veterinary Internal Medicine's Forum, Charlotte, North Carolina, June 4–8, 2003, Abstract #11.
- Elyar J.S., Tellier M.C., Soos J.M., Yamamoto J.K. Perspectives on FIV vaccine development, Vaccine 15, 1997, 1437–1444. - PubMed
- Felsenstein J. PHYLIP-phylogeny inference package, Cladistics 5, 1989, 164–166.
- Ford R.B. Sounding board. Response from the author, North American Veterinary Conference Clinician's Brief 2, 2003, 17.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources